Our study aimed to evaluate the correlation between test reagent specific gene test results and the efficacy of relevant targeted drugs in patients with non-small cell lung cancer, and to support the continued registration of test reagents.

Inclusion Criteria:

• 1)≥18，advanced non-small cell lung cancer confirmed by histopathology, and were previously or currently treated with gefitinib tablets (as the first-line treatment) or osimertinib (first-generation TKI resistance treatment) or crizotinib capsules monotherapy were evaluated for efficacy.
• 2) Able to provide FFPE samples with a storage life of 5 years: Large specimen 5 pieces in each case; 10 puncture specimens in each case

Exclusion Criteria:

• 1) Pathological evaluation of the tissue sample has too few tumor cells (total number of tumor cells >20%);
• 2) Combination therapy with chemotherapy/radiotherapy/other targeted drugs/immunotherapy drugs;
• 3) Maintenance treatment when the disease does not progress after other anti-tumor treatments.

Patients with non-small cell lung cancer who have previously received single-agent K therapy